Fulvestrant 250 mg/5 mL solution for injection — generic (India) Faslodex is indicated: as monotherapy for the treatment of locally advanced or metastatic estrogen-receptor-positive breast cancer. +380996042415

Faslodex is indicated:

 as monotherapy for the treatment of locally advanced or metastatic estrogen-receptor-positive breast cancer in postmenopausal women:

 previously naive to endocrine therapy, or

 in case of disease recurrence during or after adjuvant antiestrogen therapy or disease progression during antiestrogen therapy;

 in combination with palbociclib for the treatment of hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in women who have received prior endocrine therapy (see Pharmacodynamics).

 In premenopausal or perimenopausal women, combination therapy with palbociclib should be administered in combinations with a luteinizing hormone-releasing hormone (LHRH) agonist.